BTIG analyst Jeet Mukherjee raised the firm’s price target on Kymera Therapeutics (KYMR) to $75 from $59 and keeps a Buy rating on the shares. The stock has been the company’s top pick in the second half of 2025, having gone up 32% since July 1st, with the focus continuing to be on the phase 1b data in moderate to severe atopic dermatitis patients expected this quarter for KT-621, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics initiated with an Outperform at Mizuho
- Kymera Therapeutics price target raised to $80 from $60 at Citi
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan